Merck & Co Inc (NYSE:MRK)
$ 129.8 -0.58 (-0.44%) Market Cap: 328.76 Bil Enterprise Value: 358.57 Bil PE Ratio: 144.22 PB Ratio: 8.14 GF Score: 85/100

Merck & Co Inc Oncology Event at ASCO Transcript

Jun 07, 2021 / 10:00PM GMT
Release Date Price: $72.8 (-1.77%)
Operator

Good afternoon. My name is Lara, and I will be your conference operator today. At this time, I would like to welcome everyone to the Merck & Co. Oncology Event at ASCO 2021 Webcast Conference Call. (Operator Instructions) I would now like to turn the call over to Peter Dannenbaum, Vice President, Investor Relations. Sir, the floor is yours.

Peter Dannenbaum
Merck & Co., Inc. - VP of IR

Thank you, Lara, and good evening, everyone. Welcome to Merck's 2021 ASCO Investor Call. Dr. Dean Li, President of Merck Research Labs, will lead off our presentation with an overview of our oncology program. He will be followed by Dr. Roy Baynes, Head of Global Clinical Development, who will provide Merck's ASCO data highlights; Dr. Vicki Goodman, Head of Late-stage Oncology Development; and Dr. Eric Rubin, Head of Early-stage Oncology Development, will provide insights into several of our development programs; Jannie Oosthuizen, Head of Oncology Human Health, will provide a commercial perspective; Frank Clyburn, President of Human Health, will be available for the Q&amp

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot